Analyst consensus rating
Alnylam Pharmaceuticals Analyst Rating: Buy
Direct answer
Alnylam Pharmaceuticals's consensus rating is Buy.
26 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $371.35.
Forecast evidence checked September 16, 2026.
Get free Alnylam Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $238.27
- Average price target
- $371.35
- High price target
- $536.00
- Low price target
- $256.00
- Low target gap
- +7.4%
- Target upside
- +55.9%
- High target gap
- +125%
- Target range width
- 117.5%
- Consensus rating
- Buy
- Analysts
- 26
- Evidence date
- September 16, 2026
- Valid through
- September 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $371.35.
How far are Alnylam Pharmaceuticals's low and high targets from the recorded price?
The low target implies +7.4%, while the high target implies +125%.
How many analysts are included in Alnylam Pharmaceuticals's consensus?
The verified consensus includes 26 analysts.
How is Alnylam Pharmaceuticals's target upside or downside calculated?
The average target of $371.35 is divided by the recorded price of $238.27, then one is subtracted to produce +55.9%. This does not guarantee a future return.
When was Alnylam Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-16. The dataset is valid through 2026-09-23.